Birchview Capital, LP
- SEC CIK
- 0001618205
- Latest filing
- Aug 14, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Jun 30, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 68
- +7 vs. Q3 2024
- Portfolio value
- $122.9M
- +$7.42M (+6.4%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| BMYBristol Myers Squibb Co | Stock | 685,182 | $38.8M | 31.5% | −1,000−0.1% | Reduced | History |
| BDSXBiodesix Inc | COM | 5,736,113 | $8.78M | 7.1% | +40,000+0.7% | Added | History |
| ACADAcadia Pharmaceuticals Inc | COM | 338,400 | $6.21M | 5.1% | −62,000−15.5% | Reduced | History |
| ELUTElutia Inc. | CL A COM | 1,225,489 | $4.58M | 3.7% | −95,726−7.2% | Reduced | History |
| PRTAProthena Corp Public Ltd Co | SHS | 304,574 | $4.22M | 3.4% | +95,000+45.3% | Added | History |
| NBIXNeurocrine Biosciences Inc | Stock | 30,240 | $4.13M | 3.4% | 00.0% | Unchanged | History |
| CORTCorcept Therapeutics Inc | COM | 74,000 | $3.73M | 3.0% | 00.0% | Unchanged | History |
| UTHRUnited Therapeutics Corp | COM | 10,000 | $3.53M | 2.9% | 00.0% | Unchanged | History |
| AXGNAxogen, Inc. | COM | 197,000 | $3.25M | 2.6% | 00.0% | Unchanged | History |
| DCGODocGo Inc. | COM | 764,062 | $3.24M | 2.6% | +249,062+48.4% | Added | History |
| QDELQuidelOrtho Corp | COM | 67,619 | $3.01M | 2.5% | 00.0% | Unchanged | History |
| PHRPhreesia, Inc. | COM | 114,700 | $2.89M | 2.3% | 00.0% | Unchanged | History |
| TVTXTravere Therapeutics, Inc. | COM | 148,000 | $2.58M | 2.1% | 00.0% | Unchanged | History |
| MASIMasimo Corp | COM | 15,280 | $2.53M | 2.1% | 00.0% | Unchanged | History |
| HROWHarrow, Inc. | COM | 72,910 | $2.45M | 2.0% | 00.0% | Unchanged | History |
| STOKStoke Therapeutics, Inc. | COM | 210,000 | $2.32M | 1.9% | 00.0% | Unchanged | History |
| OVVOvintiv Inc. | COM | 52,200 | $2.11M | 1.7% | 00.0% | Unchanged | History |
| CSTLCastle Biosciences Inc | COM | 78,000 | $2.08M | 1.7% | +20,000+34.5% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 48,000 | $1.85M | 1.5% | 00.0% | Unchanged | History |
| EQTEQT Corp | Stock | 34,619 | $1.60M | 1.3% | 00.0% | Unchanged | History |
| FHTXFoghorn Therapeutics Inc. | COM | 310,930 | $1.47M | 1.2% | −10,000−3.1% | Reduced | History |
| ALKSAlkermes plc. | SHS | 50,000 | $1.44M | 1.2% | 00.0% | Unchanged | History |
| TMCITreace Medical Concepts, Inc. | COM | 161,350 | $1.20M | 1.0% | +93,000+136.1% | Added | History |
| NVCRNovoCure Ltd | ORD SHS | 31,000 | $923.8K | 0.8% | +11,000+55.0% | Added | History |
| TXG10x Genomics, Inc. | CL A COM | 50,000 | $718.0K | 0.6% | +20,000+66.7% | Added | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 16,000 | $673.1K | 0.5% | +16,000 | New | History |
| XNCRXencor Inc | COM | 26,000 | $597.5K | 0.5% | +13,700+111.4% | Added | History |
| KNSAKiniksa Pharmaceuticals International, plc | COM CL A | 30,000 | $593.4K | 0.5% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 67,000 | $567.5K | 0.5% | −15,000−18.3% | Reduced | History |
| ATECAlphatec Holdings, Inc. | COM NEW | 58,000 | $532.4K | 0.4% | −140,000−70.7% | Reduced | History |
| CADLCandel Therapeutics, Inc. | COM | 60,000 | $520.8K | 0.4% | +60,000 | New | History |
| WVEWave Life Sciences, Inc. | SHS | 40,000 | $494.8K | 0.4% | 00.0% | Unchanged | History |
| INBXInhibrx Biosciences, Inc. | COM | 32,110 | $494.5K | 0.4% | 00.0% | Unchanged | History |
| HALOHalozyme Therapeutics, Inc. | COM | 10,000 | $478.1K | 0.4% | 00.0% | Unchanged | History |
| CYTKCytokinetics Inc | COM NEW | 10,000 | $470.4K | 0.4% | 00.0% | Unchanged | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 14,000 | $446.7K | 0.4% | 00.0% | Unchanged | History |
| SRPTSarepta Therapeutics, Inc. | COM | 3,500 | $425.6K | 0.3% | +1,000+40.0% | Added | History |
| OMOutset Medical, Inc. | COM | 368,766 | $409.3K | 0.3% | +358,766+3,587.7% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 10,000 | $392.0K | 0.3% | 00.0% | Unchanged | History |
| AXDXAccelerate Diagnostics, Inc | COM | 325,239 | $390.3K | 0.3% | 00.0% | Unchanged | History |
| TELATELA Bio, Inc. | COM | 125,000 | $377.5K | 0.3% | +125,000 | New | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 10,000 | $361.3K | 0.3% | 00.0% | Unchanged | History |
| QUREuniQure N.V. | SHS | 20,000 | $353.2K | 0.3% | 00.0% | Unchanged | History |
| LUNGPulmonx Corp | COM | 51,000 | $346.3K | 0.3% | +51,000 | New | History |
| SRRKScholar Rock Holding Corp | COM | 8,000 | $345.8K | 0.3% | +8,000 | New | History |
| AXSMAxsome Therapeutics, Inc. | COM | 4,000 | $338.4K | 0.3% | 00.0% | Unchanged | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 40,000 | $300.8K | 0.2% | 00.0% | Unchanged | History |
| ATRAAtara Biotherapeutics, Inc. | COM NEW | 22,000 | $292.8K | 0.2% | +22,000 | New | History |
| ARVNArvinas, Inc. | COM | 15,000 | $287.6K | 0.2% | 00.0% | Unchanged | History |
| KPTIKaryopharm Therapeutics Inc. | COM | 419,832 | $283.9K | 0.2% | −50,000−10.6% | Reduced | History |
| BHVNBiohaven Ltd. | COM | 7,365 | $275.1K | 0.2% | 00.0% | Unchanged | History |
| FOLDAmicus Therapeutics, Inc. | COM | 28,000 | $263.8K | 0.2% | 00.0% | Unchanged | History |
| CGEMCullinan Therapeutics, Inc. | COM | 20,000 | $243.6K | 0.2% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 15,000 | $237.4K | 0.2% | +8,000+114.3% | Added | History |
| BPMCBlueprint Medicines Corp | COM | 2,700 | $235.5K | 0.2% | 00.0% | Unchanged | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 4,000 | $216.6K | 0.2% | +4,000 | New | History |
| ZBIOZenas BioPharma, Inc. | COM | 16,500 | $135.1K | 0.1% | +16,500 | New | History |
| Direxion Shs ETF Tr25459W102 | DLY TECH BULL 3X | 18,000 | $127.8K | 0.1% | +18,000 | New | – |
| GOSSGossamer Bio, Inc. | COM | 138,176 | $125.0K | 0.1% | 00.0% | Unchanged | History |
| IFRXInflaRx N.V. | COM | 50,000 | $123.5K | 0.1% | 00.0% | Unchanged | History |
| LQDALiquidia Corp | COM NEW | 10,000 | $117.6K | 0.1% | 00.0% | Unchanged | History |
| CHRSCoherus Oncology, Inc. | COM | 82,000 | $113.2K | 0.1% | −290,000−78.0% | Reduced | History |
| NPCENeuroPace Inc | COM | 10,000 | $111.9K | 0.1% | +10,000 | New | History |
| ALMSAlumis Inc. | COM | 10,000 | $78.6K | 0.1% | 00.0% | Unchanged | History |
| VTYXVentyx Biosciences, Inc. | COM | 28,800 | $63.1K | 0.1% | 00.0% | Unchanged | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 17,000 | $51.5K | <0.1% | +1,000+6.3% | Added | History |
| TSVT2seventy bio, Inc. | COMMON STOCK | 15,833 | $46.5K | <0.1% | 00.0% | Unchanged | History |
| CEROCero Therapeutics Holdings, Inc. | CLASS A COM | 12,972 | $778 | <0.1% | 00.0% | Unchanged | History |
Sold out since Q3 2024 (3)
Positions held at the end of Q3 2024 that are gone from this filing.